Market Cap 12.63M
Revenue (ttm) 0.00
Net Income (ttm) -18.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 37,600
Avg Vol 101,926
Day's Range N/A - N/A
Shares Out 3.92M
Stochastic %K 97%
Beta 2.13
Analysts Strong Sell
Price Target $21.50

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 896 9100
Website: imunon.com
Address:
997 Lenox Drive, Suite 100, Lawrenceville, United States
ConcernedCitizen23
ConcernedCitizen23 Apr. 3 at 4:17 PM
$IMNN I’ve always said this is an easy 30-50x and fully believe it ! 2 extra years of life in phase 2?!? Phase 3 will blow the doors off!
2 · Reply
RaKa82
RaKa82 Apr. 2 at 8:41 PM
$IMNN relatively strong this week. Outperformed XBI and broader markets.
0 · Reply
bxp2390
bxp2390 Apr. 2 at 6:56 PM
$IMNN Talking about Imunon or Celsion, almost the entire C-suite and operational leadership is new and never knew anything about Celsion. This includes the CEO, CMO, SVP Operations and General Counsel. Imunon's product is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. It's an immunotherapy that uses plasmid DNA to stimulate an immune response, rather than a liposomal chemotherapy delivery system like before. They are completely different products targeting different cancers with different mechanisms of action. The company shifted its strategic focus from heat-activated liposomal drug delivery (ThermoDox for liver cancer) to DNA-based immunotherapy (IMNN-001 for ovarian cancer), which is exactly why the name was changed to "Imunon" to reflect the immunotherapy focus.
0 · Reply
jjegglie
jjegglie Apr. 2 at 6:02 PM
$IMNN Nice try scumbag. Not a short. If you had done your research on my profile same as i have done with yours, you would know without a doubt why I'm here. To educate. Furthermore, no hedge funds have any interest in a $9MILLION stock. This point should be obvious without explanation. Next, clinicians, people at the FDA and others run trials because the data superficially justifies it in combination with getting paid to do so. Peddling an outwardly effective appearing drug to desperately sick people isn't particularly tough. Finally, I told you to go research the history of celsion. Clearly you did not. This current trial is nothing but a boiler plate repeat of HEAT being run by the exact same bunch of crooks.
3 · Reply
bxp2390
bxp2390 Apr. 2 at 4:29 PM
$IMNN Seeing more complains here that market doesn't believe in Phase 2 data. We know that p3 enrollment is going faster than expected and sites are coming on board (clinical trials dot org has trial sites and you can see the ones signed up). Scientists and clinicians there understand both the data and the mechanism of action of this much better than most of us. If they are choosing to sign up for this there is significant information that choice decision these sites are making. Poor products with bad data always find it hard to enroll patients, and that is the most important signal to look for when trying to understand likely success and value. That is not the case here. But if you as an investor put more faith in a hedge fund manager who is short the stock than the scientists and clinicians signing up then that's up to you when the bill comes due. There is uncertainty in any drug of course, but not like what some of the posts here are trying to suggest.
0 · Reply
bomber1
bomber1 Apr. 2 at 9:52 AM
$IMNN but above all, because the managers have lost all credibility, having made 7 offerings and 7 capital increases since 1986, burning billions of dollars in 40 years and without ever having an approved product!!!
2 · Reply
bomber1
bomber1 Apr. 2 at 9:50 AM
$IMNN imunon is valued at 10 million dollars because market does not believe phase 2 data; enormous dilution risk; poor visibility; management not credible; perceived very high risk of failure!!!!!! this is why other biotechs, in the conditions of Imunon Inc, are worth from 500 to a billion dollars; while this company struggles to stay in the 10 million... simple!!!
0 · Reply
RaKa82
RaKa82 Apr. 1 at 11:45 PM
$IMNN one thing that continues to be under appreciated here is that Ovation 3 is powered for almost certain success AND for a very early interim readout that can support a bla. If they can continue to drive/accelerate enrollment and get patients on therapy, a readout would come much sooner than many some think
0 · Reply
ZacksSCR
ZacksSCR Apr. 1 at 3:17 PM
$IMNN: Enrollment in Phase 3 OVATION 3 Trial Remains Ahead of Schedule https://buff.ly/254Tg6g
0 · Reply
RaKa82
RaKa82 Apr. 1 at 2:28 PM
$IMNN transcripts of earnings call for those (like me) who didn’t dial in. No concrete details on financing/partnerships. Lots of aspirational language and they suggest discussions have increased, but no real prospects yet is my read https://share.google/MIEMZ0yu8ocgf7VxP
0 · Reply
Latest News on IMNN
IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 28, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value


IMUNON Announces Reverse Stock Split

Jul 23, 2025, 8:00 AM EDT - 9 months ago

IMUNON Announces Reverse Stock Split


IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 22, 2025, 5:20 PM EDT - 11 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement


IMUNON Appoints Douglas V. Faller, M.D.

Feb 10, 2025, 8:05 AM EST - 1 year ago

IMUNON Appoints Douglas V. Faller, M.D.


ConcernedCitizen23
ConcernedCitizen23 Apr. 3 at 4:17 PM
$IMNN I’ve always said this is an easy 30-50x and fully believe it ! 2 extra years of life in phase 2?!? Phase 3 will blow the doors off!
2 · Reply
RaKa82
RaKa82 Apr. 2 at 8:41 PM
$IMNN relatively strong this week. Outperformed XBI and broader markets.
0 · Reply
bxp2390
bxp2390 Apr. 2 at 6:56 PM
$IMNN Talking about Imunon or Celsion, almost the entire C-suite and operational leadership is new and never knew anything about Celsion. This includes the CEO, CMO, SVP Operations and General Counsel. Imunon's product is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. It's an immunotherapy that uses plasmid DNA to stimulate an immune response, rather than a liposomal chemotherapy delivery system like before. They are completely different products targeting different cancers with different mechanisms of action. The company shifted its strategic focus from heat-activated liposomal drug delivery (ThermoDox for liver cancer) to DNA-based immunotherapy (IMNN-001 for ovarian cancer), which is exactly why the name was changed to "Imunon" to reflect the immunotherapy focus.
0 · Reply
jjegglie
jjegglie Apr. 2 at 6:02 PM
$IMNN Nice try scumbag. Not a short. If you had done your research on my profile same as i have done with yours, you would know without a doubt why I'm here. To educate. Furthermore, no hedge funds have any interest in a $9MILLION stock. This point should be obvious without explanation. Next, clinicians, people at the FDA and others run trials because the data superficially justifies it in combination with getting paid to do so. Peddling an outwardly effective appearing drug to desperately sick people isn't particularly tough. Finally, I told you to go research the history of celsion. Clearly you did not. This current trial is nothing but a boiler plate repeat of HEAT being run by the exact same bunch of crooks.
3 · Reply
bxp2390
bxp2390 Apr. 2 at 4:29 PM
$IMNN Seeing more complains here that market doesn't believe in Phase 2 data. We know that p3 enrollment is going faster than expected and sites are coming on board (clinical trials dot org has trial sites and you can see the ones signed up). Scientists and clinicians there understand both the data and the mechanism of action of this much better than most of us. If they are choosing to sign up for this there is significant information that choice decision these sites are making. Poor products with bad data always find it hard to enroll patients, and that is the most important signal to look for when trying to understand likely success and value. That is not the case here. But if you as an investor put more faith in a hedge fund manager who is short the stock than the scientists and clinicians signing up then that's up to you when the bill comes due. There is uncertainty in any drug of course, but not like what some of the posts here are trying to suggest.
0 · Reply
bomber1
bomber1 Apr. 2 at 9:52 AM
$IMNN but above all, because the managers have lost all credibility, having made 7 offerings and 7 capital increases since 1986, burning billions of dollars in 40 years and without ever having an approved product!!!
2 · Reply
bomber1
bomber1 Apr. 2 at 9:50 AM
$IMNN imunon is valued at 10 million dollars because market does not believe phase 2 data; enormous dilution risk; poor visibility; management not credible; perceived very high risk of failure!!!!!! this is why other biotechs, in the conditions of Imunon Inc, are worth from 500 to a billion dollars; while this company struggles to stay in the 10 million... simple!!!
0 · Reply
RaKa82
RaKa82 Apr. 1 at 11:45 PM
$IMNN one thing that continues to be under appreciated here is that Ovation 3 is powered for almost certain success AND for a very early interim readout that can support a bla. If they can continue to drive/accelerate enrollment and get patients on therapy, a readout would come much sooner than many some think
0 · Reply
ZacksSCR
ZacksSCR Apr. 1 at 3:17 PM
$IMNN: Enrollment in Phase 3 OVATION 3 Trial Remains Ahead of Schedule https://buff.ly/254Tg6g
0 · Reply
RaKa82
RaKa82 Apr. 1 at 2:28 PM
$IMNN transcripts of earnings call for those (like me) who didn’t dial in. No concrete details on financing/partnerships. Lots of aspirational language and they suggest discussions have increased, but no real prospects yet is my read https://share.google/MIEMZ0yu8ocgf7VxP
0 · Reply
LKDOG
LKDOG Mar. 31 at 9:48 PM
$IMNN Anyone anticipating significant moves tomorrow ?
1 · Reply
bxp2390
bxp2390 Mar. 31 at 8:07 PM
$IMNN Today is why Imunon needs a banking partner that's elite. Most likely a lot of ATM sales was done at 2.90 where shares were being unloaded regardless of the market being up 1000 points. Imunon needs someone who had a formal valuation model in biotech and can attract investment at that level. Plug in the numbers into even AI today and ask it to evaluate the present value of a biotech. For sake of making it easy to do this, ask chatGPT what should be the value today of a biotech with approval in 7 years, market on approval likely 1-3 billion, approval probability 50% (average of p3), and ask it to pick the discount factor commonly used in valuation. Share here what the tool tells you.
2 · Reply
Ferryf
Ferryf Mar. 31 at 12:30 PM
$IMNN As of December 31, 2025, cash and cash equivalents were $8.8 million.
0 · Reply
Ferryf
Ferryf Mar. 31 at 12:28 PM
$IMNN The well-precedented nature of the Phase 3 trial design, which leverages an innovative, adaptive, event-driven approach aligned with prior successful oncology trials that resulted in full approval by the U.S. Food and Drug Administration (FDA) based on an interim analysis of overall survival. This foundation, supported by conservative power assumptions drawn from Phase 2 clinical data, strong simulation modeling and robust statistical properties, underpins the Phase 3 trial's high probability for success.
0 · Reply
Ferryf
Ferryf Mar. 31 at 12:25 PM
$IMNN Importantly, with these new efficacy results, IMNN-001 continued to show a highly favorable safety and tolerability profile, further reinforcing the potential of this IL-12 immunotherapy to represent a landmark advance in treatment of this disease.
0 · Reply
Ferryf
Ferryf Mar. 31 at 12:24 PM
$IMNN In addition, the new IMNN-001 data showed that women treated with IMNN-001 and SoC chemotherapy plus poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy achieved a median increase in overall survival of 24.2 months (65.6 vs. 41.4 months) compared to SoC chemotherapy alone.
0 · Reply
Ferryf
Ferryf Mar. 31 at 12:23 PM
$IMNN On March 25, 2026, the Company announced final data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT) in 112 women with newly diagnosed advanced ovarian cancer. IMUNON previously reported a median 11.1 month increase in overall survival (40.5 vs. 29.4 months) in the IMNN-001 treatment arm compared to SoC chemotherapy alone. Following the most recent data assessment, the Company reported a median 14.7 month increase in overall survival (45.1 vs. 30.4 months) in women in the IMNN-001 treatment arm compared to SoC alone, demonstrating continuous improvement in overall survival (3.6 delta).
0 · Reply
Ferryf
Ferryf Mar. 31 at 12:21 PM
$IMNN Dr. Lindborg continued Unprecedented survival data results from the Phase 2 OVATION 2 Study, coupled with compelling interim results from our MRD study and a clear regulatory path in Phase 3, position IMNN-001 with the potential to deliver transformative impact on ovarian cancer treatment. These new results showing continued improvements in overall survival are especially exciting given that there have been virtually no advances in frontline standard of care for women newly diagnosed with ovarian cancer in the last 35 years
0 · Reply
Ferryf
Ferryf Mar. 31 at 12:18 PM
$IMNN “IMUNON continues to make significant progress in advancing IMNN-001, a potential breakthrough for women with newly diagnosed advanced ovarian cancer,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “A final data assessment of the Phase 2 OVATION 2 Study indicates that treatment with IMNN-001 was associated with an overall survival benefit of more than a year in patients treated with IMNN-001 plus chemotherapy and more than two years in women also receiving PARP inhibitors as part of maintenance therapy.”
0 · Reply
Ferryf
Ferryf Mar. 31 at 12:17 PM
$IMNN IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON’s Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest from principal investigators and the medical community
0 · Reply
RaKa82
RaKa82 Mar. 31 at 12:51 AM
$IMNN Eager to hear if they share anything meaningful tomorrow. Good progress on enrollment, which they already confirmed, plus some info on patients dosed would be a good start.
1 · Reply
ChartingMasters
ChartingMasters Mar. 30 at 8:20 AM
0 · Reply